Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in small cell lung cancer
- New trial
Small cell lung cancer
Phase 3 BrenDeLL-Lung01 tests DLL3-targeted BL-M14D1 plus atezolizumab in first-line extensive-stage SCLC
SystImmune is running this global, open-label, randomized Phase 3 trial in previously untreated extensive-stage small-cell lung cancer. BL-M14D1 is a DLL3-directed antibody-drug conjugate with a topoisomerase I…
NCT07625644 Registrational - New trial
Small cell lung cancer
Phase 2 sacituzumab govitecan TROP2-directed SN-38 ADC + PD-L1 blockade maintenance in ES-SCLC
This Phase 2, open-label maintenance study tests whether adding sacituzumab govitecan (SG)—a TROP2-targeted monoclonal antibody–drug conjugate delivering the topoisomerase I inhibitor SN-38 (Gilead Sciences’…
NCT07339059 Exploratory - New trial
Small cell lung cancer
Phase 3 tarlatamab (Amgen) DLL3×CD3 bispecific T‑cell engager compares SC vs IV dosing
Amgen’s DeLLphi-315 is a Phase 3, open-label, randomized, multicenter study in relapsed extensive-stage small cell lung cancer (ES-SCLC) after platinum-based first-line chemotherapy. Participants are randomized to…
NCT07778316 Exploratory - New trial Spotlight
Small cell lung cancer
Phase 3 ABBV-706 SEZ6-targeted topo-1 ADC vs chemotherapy in R/R SCLC
AbbVie’s randomized, open-label Phase 3 trial tests ABBV-706 against physician’s-choice topotecan, lurbinectedin, or amrubicin in roughly 531 patients with relapsed/refractory SCLC. ABBV-706 is a SEZ6-directed…
NCT07365241 Registrational - Trial result
Small cell lung cancer
LIPI strongly stratifies survival in ES-SCLC but does not predict chemo-IO benefit
In a post hoc pooled analysis of the Phase 3 CASPIAN (durvalumab + platinum/etoposide) and IMpower133 (atezolizumab + carboplatin/etoposide) trials, the Lung Immune Prognostic Index (LIPI; good = dNLR<3 & LDH<ULN;…
- Trial result
Small cell lung cancer
Tarlatamab (DLL3×CD3 BiTE) MAIC suggests OS edge vs paclitaxel/CAV in platinum-refractory ES-SCLC
Tarlatamab is a DLL3×CD3 bispecific T-cell engager (BiTE) that redirects cytotoxic T cells to DLL3-expressing SCLC cells; here, an unanchored matching-adjusted indirect comparison (MAIC) used DeLLphi-304 individual…
NCT05740566 - Trial result
Small cell lung cancer
Lurbinectedin (DNA-binding transcription inhibitor) + atezolizumab extends Q‑TWiST vs atezolizumab in ES‑SCLC maintenance
Lurbinectedin (a selective inhibitor of oncogenic transcription via DNA binding) plus the PD‑L1 inhibitor atezolizumab was evaluated as first-line maintenance in the Phase 3 IMforte trial (NCT05091567) in ES‑SCLC…
NCT05091567 - Trial result
Small cell lung cancer
ABBV-706 (SEZ6-targeted Top1i ADC) posts 52% ORR in relapsed/refractory SCLC, RP2D set at 1.8mg/kg Q3W
ABBV-706 is a SEZ6-directed antibody–drug conjugate delivering a topoisomerase-1 inhibitor (Top1i) payload, evaluated in an open-label Phase 1 dose-escalation/optimization/expansion trial across advanced solid tumors…
NCT05599984 - New trial
Small cell lung cancer
Phase 3 trilaciclib CDK4/CDK6 inhibitor tests myeloprotection in limited-stage SCLC.
This Phase 3 randomized, double-blind, placebo-controlled, parallel-group trial sponsored by Pharmacosmos A/S tests whether trilaciclib—a small-molecule CDK4/CDK6 inhibitor that transiently arrests hematopoietic…
NCT07473128 Registrational - Trial result Spotlight
Small cell lung cancer
ABBV-706 (SEZ6-targeted topo-1 ADC) posts 52% ORR and 11.3-mo OS in R/R SCLC; combo with budigalimab looks feasible
ABBV-706 is a seizure-related 6 homolog (SEZ6)-targeting antibody–drug conjugate delivering a topoisomerase-1 inhibitor payload; this Phase 1 study (NCT05599984) tested ABBV-706 Q3W as monotherapy (N=124; 65% had ≥2…
NCT05599984 - Trial result
Small cell lung cancer
LB2102 (DLL3-targeted, dnTGFBR2-armored autologous CAR-T) shows early signals in R/R SCLC/LCNEC with manageable CRS/ICANS
LB2102 is an autologous DLL3-directed CAR-T cell therapy armored with a dominant-negative TGF-β receptor 2 (dnTGFBR2) to blunt TGF-β–mediated immunosuppression, evaluated in an open-label, multicenter Phase 1 i3+3…
NCT05680922 - Trial result
Small cell lung cancer
Obrixtamig DLL3×CD3 Adds 73% ORR to 1L ES-SCLC Chemo-IO
Obrixtamig (BI 764532) is an IV DLL3/CD3 IgG-like T-cell engager combined with carboplatin/etoposide/atezolizumab induction followed by obrixtamig plus atezolizumab maintenance in the Phase 1 DAREON-8 trial…
NCT06077500 - New trial
Small cell lung cancer
Phase 1/2 DJI136 (LB2102) DLL3-targeted autologous CAR‑T for extensive-stage SCLC.
This Phase 1/2, open-label, non-randomized, multi-center study sponsored by Novartis Pharmaceuticals is testing DJI136 (also described as LB2102), an autologous CAR‑T cell therapy engineered to recognize DLL3 on…
NCT07564401 First-in-human - New trial Spotlight
Small cell lung cancer
Phase 1b tarlatamab DLL3×CD3 T‑cell engager + ZL‑1310 DLL3 Topo‑I ADC ± durvalumab
Amgen’s open-label Phase 1b study tests whether dual DLL3 targeting can deepen responses in relapsed/recurrent small cell lung cancer: tarlatamab (a DLL3×CD3 bispecific antibody that redirects T cells to…
NCT07531095 Exploratory - New trial
Small cell lung cancer
Phase 2 FHD-286 SMARCA4/2 (BRG1/BRM) ATPase inhibitor in POU2F3+ SCLC
This single-arm Phase 2 study tests FHD-286, an oral small-molecule dual SMARCA4/SMARCA2 (BRG1/BRM) ATPase inhibitor that targets the SWI/SNF (BAF) chromatin remodeling complex, in people with POU2F3-expressing small…
NCT07551635 Exploratory - New trial
Small cell lung cancer
Phase 1b DSP-0390 EBP (cholesterol biosynthesis) inhibitor plus PD‑L1 mAb atezolizumab
This single-center Phase 1b pilot at Washington University in St. Louis tests whether adding DSP‑0390—an oral small-molecule inhibitor of emopamil-binding protein (EBP), a late-step sterol isomerase in de novo…
NCT07545954 Exploratory - New trial
Small cell lung cancer
Phase 2 PF-08634404 PD‑1×VEGF bispecific antibody with platinum-etoposide in T‑SCLC.
Pfizer’s Phase 2, open-label Symbiotic‑Lung‑14 study tests PF‑08634404, a PD‑1 and VEGF‑targeted bispecific antibody intended to combine checkpoint blockade with anti-angiogenic signaling inhibition, in adults with…
NCT07476287 Exploratory - Trial result Spotlight
Small cell lung cancer
ZL-1310 (DLL3-targeted topo I ADC) drives 58% intracranial responses in ES-SCLC brain mets
ZL-1310 is a DLL3-targeted antibody–drug conjugate using the TMALIN® platform (protease-cleavable linker delivering a topoisomerase I inhibitor payload) evaluated in a multi-country Phase 1 dose-escalation trial in…
NCT06179069 - New trial Spotlight
Small cell lung cancer
Phase 3 trial of tarlatamab, a DLL3/CD3 bispecific antibody, in extensive-stage SCLC.
This Phase 3 open-label, multicenter randomized trial compares tarlatamab plus durvalumab, carboplatin, and etoposide versus standard durvalumab, carboplatin, and etoposide in untreated stage IV extensive-stage…
NCT07005128 Registrational - New trial
Small cell lung cancer
Phase III BNT327 VEGFA-directed mAb trial in extensive-stage small cell lung cancer
This randomized, double-blinded study compares two treatment arms in first-line extensive-stage small cell lung cancer patients. One arm uses atezolizumab—a PD-L1 inhibitor—plus etoposide (a topoisomerase II…
NCT06712355 Registrational - New trial
Small cell lung cancer
Phase 2 trial of BMS-986489, atigotatug (anti-fucosyl-GM1 monoclonal antibody) plus PD-1 inhibitor, in SCLC consolidation
An open-label randomized study compares the fixed-dose combination of atigotatug and nivolumab (BMS-986489) with standard durvalumab consolidation following chemoradiotherapy in limited-stage small-cell lung cancer.…
NCT06773910 Exploratory - Trial result
Small cell lung cancer
Tarlatamab CD3×DLL3 T-cell engager lifts median OS to 13.6 mo after platinum-relapsed SCLC
Tarlatamab is a bispecific that redirects T cells to DLL3-positive neuroendocrine cells. In the phase 3, open-label DeLLphi-304 trial (NCT05740566) 509 small-cell lung cancer patients who had progressed on platinum…
NCT05740566 - Trial result
Small cell lung cancer
Obrixtamig (BI 764532) + Topotecan Doubles Typical Second-Line Response in Platinum-Relapsed SCLC
Obrixtamig is an IgG-like bispecific T-cell engager that binds DLL3 on tumor cells and CD3 on T cells, while topotecan is the long-standing topoisomerase-I standard for relapsed small-cell lung cancer (SCLC). In the…
NCT05990738 - New trial
Small cell lung cancer
Phase 2 Tarlatamab Trial: DLL3 and CD3-directed bispecific antibody
This open-label randomized study evaluates Tarlatamab dosing regimens in patients with relapsed or refractory small cell lung cancer. Conducted at global centers by Amgen, it examines the antitumor activity of this…
NCT06745323 - Trial result
Small cell lung cancer
Trispecific DLL3 T-Cell Engager ZG006 Delivers 67% ORR in Post-PD-1 Small-Cell Lung Cancer
ZG006 is a bispecific antibody that bridges CD3+ T cells to two DLL3 epitopes. In a Phase 2 dose-expansion study (NCT06283719) involving 40 heavily pretreated small-cell lung cancer (SCLC) patients (≥2 prior lines of…
NCT06283719 - Trial result
Small cell lung cancer
ZL-1310, a DLL3-targeted ADC, achieves a 68% response rate in relapsed/refractory ES-SCLC
Treatment options are limited for patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) that progress after platinum-based chemotherapy (chemo). In a Phase I dose-escalation (n=28), ZL-1310, a DLL3…
- Trial result
Small cell lung cancer
ZG006 Ignites T‑Cell Response in Refractory SCLC by Targeting DLL3
ZG006 is a unique designed T cell engager, targeting CD3 and Delta-like ligand 3 (DLL3) on DLL3-expressing tumor cells such as small cell lung cancer (SCLC) or neuroendocrine carcinoma (NEC). In the phase 1 study…
- Trial result
Small cell lung cancer
DLL3-Targeted LB2102 CAR-T Demonstrates Dose-Dependent Expansion and Early Efficacy in SCLC/LCNEC
LB2102 is a CAR-T therapy engineered to target DLL3 and armored with a block TGF-β receptor blockade signals. This phase 1 study (NCT05680922) so far evaluated LB2102 in nine relapsed/refractory SCLC/LCNEC patients.…
NCT05680922 - New trial
Small cell lung cancer
Phase 1 Dose Escalation Study of ZG006 in Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals is evaluating ZG006—a DLL3 and CD3 directed bispecific mAb—in small cell lung cancer patients intolerant to standard treatment, using a 3+3 dose escalation design to determine the…
NCT06592638
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.